Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Nutrition & Metabolism

Table 1 Demographic data of premenopausal female patients with Graves' disease compared to both healthy controls and patients with Hashimoto's thyroiditis on stable levothyroxine replacement.

	Controls	Graves' disease Months after diagnosis				Hashimoto's thyroiditis
Study points (months)		Baseline	3	18 ± 3	36 ± 3
Number	19	32				18
Age (years)	43	39^NS				43^NS
	(37-49)	(34-45)				(36-50)
Height (m)	1.67	1.66^NS				1.66^NS
	(164-170)	(164-169)				(162-170)
Weight (kg)	67	59^#	63*	65**	65**	67^NS
	(62-73)	(55-63)	(59-67)	(61-70)	(61-70)	(63-71)
BMI (kg/m²)	24	21^#	23*	23**	23**	24^NS
	(22-26)	(20-23)	(21-24)	(22-25)	(22-25)	(22-26)
Pregnancies (no)	0	5				0
Abortions (no)	0	3				0
Smoking (no)	2	14				8
Birth control tablets (no)	0	1				1
Calcium tablets (no)	0	1				0
TAO (no)	0	5				0
Prednisone (no)	0	1				0

Data are expressed as antilog mean (CI 95%) and significance is marked as * = p < 0.05,
** = p < 0.005 when compared to baseline and marked differently as^# = p < 0.05, ^## = p < 0.005 when normal controls are compared to baseline data for patient with Graves' disease or patients with Hashimoto's disease. NS = non-significant. No=number of persons. TAO=thyroid associated ophthalmopathy.

ISSN: 1743-7075